Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics today and set a price target of $258.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.2% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $297.00 price target.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics today and set a price target of $258.00.

According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.2% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical.

In a report released today, RBC Capital also maintained a Buy rating on the stock with a $297.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.